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Abstract
The second-generation pericardial valve, the Carpentier-Edwards perimount bioprosthetic (CEP) valve, shows
dramatically improved durability as compared to the first-generation pericardial valve, and excellent performance
has been obtained, in both the aortic and mitral positions. Especially in elderly patients with an implanted CEP
valve, reoperation due to structural valve deterioration (SVD) is rarely required. Here, we report the case of an 87-
year-old woman with an explanted CEP valve in the mitral position due to SVD, 16 years after its implantation.
An 87-year-old woman was admitted to our hospital
with acute heart failure, NYHA class IV. An echocardio-
graphy revealed severe mitral regurgitation and heart
failure with pulmonary hypertension. She had been diag-
nosed as having severe mitral stenosis and had under-
gone mitral valve replacement with a 27-mm
Carpentier-Edwards mitral pericardial valve (model
6900) 16 years prior (at 71 years old) to the present
admission. An echocardiography performed 3 months
prior to this admission revealed mild mitral stenosis and
regurgitation; however, there were no associated clinical
symptoms. Prior to the present admission, she was
brought to the hospital with dyspnea of acute onset. A
transesophageal echocardiogram revealed severe mitral
regurgitation due to structural valve deterioration (SVD)
of the implanted CEP valve, moderate TR, and severe
pulmonary hypertension, with a PAP of 93 mm Hg
(Figure 1). She was initially treated with furosemide and
cariperitide, which produced slight improvement of the
heart failure; however, reoperation was found to be
necessary. The reoperation was performed 9 days after
admission via a median sternotomy and under moderate
hypothermic cardiopulmonary bypass with antegrade
cold crystalloid cardioplegic arrest. The mitral valve was
examined through an incision in the left atrium. A tear
was noted in one of the leaflets of the implanted CEP
mitral valve, which was thought to be the cause of the
severe mitral regurgitation. The cuff of the valve was
covered with thick intima; however, the leaflets were
relatively soft. The valve was resected, and a 27-mm
Mosaic mitral bioprosthesis was implanted in its place.
Tricuspid valve ring annuloplasty was performed with a
30-mm MC3. The patient was extubated on the day
after the surgery and discharged from our hospital on
day 20 after the operation.
The macroscopic findings of the deteriorated valve
were as follows (Figure 2A, B): The stenosis of the valve
was caused by the host tissue overgrowth restricting the
mobility of the leaflets. A tear was evident in leaflet 1 at
commissure 2, which measured approximately 14 mm,
beginning from the commissure, along the ring of the
prosthetic valve.
Calcification was detected in the x-ray on leaflets 2
and 3, which were covered by a dense layer of host tis-
sue overgrowth (Figure 2C).
Discussion
Marchand et al. reported an actuarial freedom rate from
structural valve deterioration (SVD) in patients receiving
implantation of the CEP valve, 6900 model, in the mitral
position of 59.2%±6.6% in patients under 60 years of age,
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and 100% in patients over 70 years of age [1]. A literature
search to the best of our ability revealed no cases that had
undergone CEP valve implantation in the mitral position
at more than 70 years of age, with subsequent SVD and
explantation of the valve. The average life expectancy of
Japanese is quite long, being 79.59 years in males and
86.44 years in females, and the average expected length of
life at 70 years is 15.1 years in males and 19.61 years in
females (Japan Ministry of Health and Welfare 2009
http://www.mhlw.go.jp/toukei/saikin/hw/life/life09/). Our
patient had undergone her first implantation of a mitral
bioprosthetic valve at the age of 71 years; her postopera-
tive course had been excellent, and her condition had
remained satisfactory for more than 15 years without war-
farin. Unfortunately, she developed SVD suddenly, 16
years after the valve implantation, and needed a reopera-
tion at the age of 87 years. However, she was healthy
enough even at this age to tolerate heart surgery.
Bioprosthetic valve implantation in the mitral position
is usually performed in patients who are more than 60
or 70 years old. As reported here, especially in Japanese
subjects who have a long life expectancy, SVD of an
implanted valve at over 70 years of age may occur, pos-
sibly necessitating reoperation. Notwithstanding, bio-
prosthetic valves must be selected for elderly patients,
considering the risk of thromboembolism, and conse-
quently of hemorrhage associated with the use of war-
farin, in patients with a mechanical valve. Cannegier et
al. reported that the risk of hemorrhage in patients over
70 years of age with an implanted mechanical valve was
5.6%/pt-year, which is twice as high as the risk reported
in patients who are less than 70 years old [2]. Holper et
al. reported that the actuarial freedom rate from major
bleeding at 15 years was 88%±4% in patients with an
implanted bioprosthetic valve, and 57%±1.1% in those
with an implanted mechanical valve [3]. In agreement
with this, Marchand et al. reported that the actuarial
freedom rate from major bleeding in patients with an
implanted CEP valve was 86.6%±3.2% at 14 years [1].
These data suggest that a bioprosthetic valve is superior
to a mechanical valve from the viewpoint of the risk of
major bleeding. As reoperation can also be performed
safely in elderly patients at present, it might be better to
select a bioprosthetic valve for elderly patients, notwith-
standing the risk of reoperation due to SVD more than
10 years later [4].
In regard to the pattern of SVD of a CEP valve, calcifi-
cation (70.4%-73%), valve tear (18.5%-20%), or and both
(7%-11.1%) have been reported [1,5]. The main cause of
SVD in our present patient was a tear of one of the
valve leaflets, which probably occurred suddenly, causing
severe mitral regurgitation and heat failure. The torn
leaflet showed no calcification on a plain radiograph,
while the other two leaflets showed calcification. The
differential calcification of the leaflets of the same CEP
valve is thought to be related to the different bovine ori-
gin of the component tissues of the valve. The imbal-
ance of calcification in the three leaflets can cause
imbalance of the tension between these leaflets, increas-
ing the risk of leaflet tear [6,7]. In our patient, the tear
was noted in the leaflet that showed no calcification,
while the other two leaflets showed calcification. An
interesting report on the Mosaic valve, which is of single
porcine origin, indicates excellent durability of the valve
in the mitral position, with no evidence of SVD at 10
years [8]. If this is true, the different pattern of SVD of
the CEP valve, especially the occurrence of the tear, may
be attributable to its different origin. On the other hand,
the quality of each component could also be different
even in the single porcine valve, hence further investiga-
tion is necessary.
In conclusion, in Japanese patients with a high life
expectancy, SVD of an implanted bioprosthetic valve
can occur in patients undergoing the valve surgery even
Figure 1 Echocardiography revealing prolapse of the
Carpentier-Edwards Perimount bioprosthesis (white arrow) (A)
and severe mitral regurgitation (B).
Figure 2 Explanted Carpentier-Edwards Perimount
bioprosthesis (view from the left ventricule: A, view from the left
atrium: B showing a tear in leaflet 1 (white arrow). X-ray of the valve
showed calcification on leaflets 2 and 3, but not on leaflet 1 (C).
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implant bioprosthetic valves for elderly patients to avoid
the risk of major bleeding, reoperation may become
necessary in patients living long after the surgery. We
have described the first case of a patient who developed
SVD and explantation of a CEP valve, 16 years after it
was implanted, in a patient who was over 70 years of
age at the time of the surgery.
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